In line with this rationale, we recently discovered that UHRF1 downmodulation in RB cells increases the sensitivity to conventional genotoxic drugs, which are widely used for chemoreduction as the first‐line therapy for RB (He et al., 2018). The gene discussed is UHRF1; the disease is retinoblastoma.